Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Eli Lilly and Company (LLY): A Bull Case Theory [Yahoo! Finance]
Eli Lilly and Company (NYSE:LLY) was given a new $1,200.00 price target on by analysts at BMO Capital Markets.
Companies Cut Prices For Blockbuster Weight-Loss Drugs [Forbes]
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor [Yahoo! Finance]